Treatment of Patients Suffering from Tumour Cachexia with Dronabinol (tetrahydrocannabinol) or PlaceboComparison of individually optimised dosages in a double blind, randomised parallel design - Dronabinol for tumour cachexia

Department of Medicine I, Clinical Dep. f. Oncology, University Hospital,0 个研究点目标入组 74 人开始时间: 2007年10月30日最近更新: 2012年3月19日

试验速览

暂无简介。

•Patients with tumour cachexia as patients with a loss of 3% or more of body weight during a period of up to 8 weeks preceding inclusion and fulfilling all in- and exclusion criteria
•Patients with the following diagnosis according to ICD-10 are eligible: N. Bronchi, C 34.9, no CNS metastases
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•life expectancy < 2 months
•subjects who are not available over a period of at least 8 weeks,
•suspected ileus or other intestinal disorders including gastritis or bowel dysfunction
•pancreatitis or pancreatic cancer
•any known abuse of marijuana or a history of abuse of marijuana
•serious concomitant medical illness/concomitant disease(s) which would preclude the patient from participating (e.g., serious psychiatric illness that would interfere with obtaining informed consent etc.),
•participation in an experimental trial within the last 4 weeks
•subjects where no written informed consent is received
•female subjects of child bearing potential in which a pregnancy has not been ruled out by appropriate tests (fertile women must practice adequate contraception throughout the course of the study);

发起方

Department of Medicine I, Clinical Dep. f. Oncology, University Hospital,